Connecting Lateral Flow to the 21st Century.
To find out more about Bond Health, I spoke to Phil Groom, Commercial Director, and Viktoriya Agova, Marketing Manager from Bond Health to hear how they're connecting the world of lateral flow.
Reported to correct 89% of pathogenic human gene variants, prime gene editing has the potential to target over 75,000 different mutations in treatment.
A new generation of start-ups are revolutionising cancer diagnosis, detecting disease before patients even show symptoms with liquid biopsy tests. This innovation is rife in the US.